Mutz et al. (2017). EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. Oncotarget.
Sheffield et al. (2017). DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nature Medicine.
Schwentner et al. (2016). The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma. Oncotarget.
Gordon et al. (2016). Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. Oncogene.
Krook et al. (2016). A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma. Oncotarget.
Goss, and Gordon (2016). Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget.
Hingorani et al. (2016). Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genetics.
Theisen et al. (2016). Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget.
Osgood et al. (2016). Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical Cancer Research.
Kovar et al. (2016). The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget.
Lawlor, and Sorensen (2015). Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?. Critical Reviews in Oncogenesis.
Zhang et al. (2015). Germline Mutations in Predisposition Genes in Pediatric Cancer. New England Journal of Medicine.
Abbott et al. (2015). Abstract 2748: A population-based survey of excess cancers observed in Ewingtextquotesingles sarcoma and in their first-, second-, and third-degree relatives. Cancer Research.
Gomez, and Davis (2015). Linking germline and somatic variation in Ewing sarcoma. Nature Genetics.
Grünewald et al. (2015). Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nature Genetics.
Agelopoulos et al. (2015). Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. Clinical Cancer Research.
Fadul et al. (2015). EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma. Genes \& cancer.
Tang et al. (2015). SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clinical Cancer Research.
Tomazou et al. (2015). Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Reports.
Schwentner et al. (2015). EWS-FLI1 employs an E2F switch to drive target gene expression. Nucleic Acids Research.
Riggi et al. (2014). EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma. Cancer Cell.
Choy et al. (2014). Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. {BMC} Cancer.
Toretsky, and Wright (2014). Assemblages: functional units formed by cellular phase separation. The Journal of cell biology.
Tirode et al. (2014). Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discovery.
Cornaz-Buros et al. (2014). Targeting Cancer Stem-like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing Sarcoma. Cancer Research.
Crompton et al. (2014). The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery.
Monument et al. (2014). Clinical and Biochemical Function of Polymorphic NR0B1 GGAA-Microsatellites in Ewing Sarcoma: A Report from the Childrentextquotesingles Oncology Group. {PLoS} {ONE}.
Brohl et al. (2014). The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation. {PLoS} Genetics.
Kayarthodi et al. (2014). Anti-Epileptic Drug Targets Ewing Sarcoma. Journal of Pharmaceutical Sciences and Pharmacology.
Sankar et al. (2014). Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth. Clinical Cancer Research.
Sankar et al. (2014). Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clinical cancer research.
Arnaldez, and Helman (2014). New Strategies in Ewing Sarcoma: Lost in Translation?. Clinical Cancer Research.
Zhou et al. (2014). EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer.
Walters et al. (2014). JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene.
Grohar et al. (2013). Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth. Clinical Cancer Research.
Stoll et al. (2013). Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic acids research.
Niedan et al. (2013). Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene.
Bilke et al. (2013). Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Research.
Sankar et al. (2013). EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma. Genes \& cancer.
Crompton et al. (2013). High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma. Cancer Research.
Sankar et al. (2012). Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene.
David et al. (2012). Oncostatin M is a growth factor for Ewing sarcoma. The American journal of pathology.
De Vito et al. (2012). A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer cell.
Lawlor, and Thiele (2012). Epigenetic changes in pediatric solid tumors: promising new targets. Clinical cancer research.
Reynolds et al. (2012). NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity and lineage commitment. Cell stem cell.
Baruchel et al. (2012). A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group. European Journal of Cancer.
Postel-Vinay et al. (2012). Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics.
Patel et al. (2012). Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome research.
Lessnick, and Ladanyi (2012). Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annual review of pathology.
Juergens et al. (2011). Preliminary Efficacy of the Anti-InsulintextendashLike Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma. Journal of Clinical Oncology.
Grohar et al. (2011). Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening. {JNCI} Journal of the National Cancer Institute.
von Levetzow et al. (2011). Modeling Initiation of Ewing Sarcoma in Human Neural Crest Cells. {PLoS} {ONE}.
Grohar et al. (2011). Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells. Neoplasia.
Lin et al. (2011). Mesenchymal Stem Cells and the Origin of Ewing’s Sarcoma. Sarcoma.
Desai, and Jambhekar (2010). Pathology of Ewing’s sarcoma/PNET: Current opinion and emerging concepts. Indian journal of orthopaedics.
Erkizan et al. (2010). Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing’s sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research.
Riggi et al. (2010). EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes and Development.
Le Deley et al. (2010). Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Erkizan et al. (2009). A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewingtextquotesingles sarcoma. Nature Medicine.
Houghton (2009). How do we identify novel treatment for childhood cancer?. Pediatric Blood {\&} Cancer.
DuBois et al. (2009). Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Childrentextquotesingles Oncology Group. Pediatric Blood {\&} Cancer.
Suva et al. (2009). Identification of Cancer Stem Cells in Ewingtextquotesingles Sarcoma. Cancer Research.
Guillon et al. (2009). The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PloS one.
Stegmaier et al. (2007). Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma. {PLoS} Medicine.
Kennedy, and DtextquotesingleAndrea (2006). DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes. Journal of Clinical Oncology.
Amann et al. (1999). Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. Human pathology.
Toretsky et al. (1997). The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts. Journal of Biological Chemistry.
Delattre et al. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature.
Rud et al. (1989). Extraosseous Ewing’s sarcoma. A study of 42 cases. Cancer.